NCT05644717 (Ertu-NASH) is a Phase 4 clinical trial of Ertugliflozin 5 mg, 15mg in Liver Fat, sponsored by Getz Pharma.

Who is sponsoring NCT05644717?

NCT05644717 is sponsored by Getz Pharma.

What drugs are being tested in NCT05644717?

Interventions in NCT05644717: Ertugliflozin 5 mg, 15mg.

What condition does NCT05644717 study?

NCT05644717 studies Liver Fat, Liver Fibrosis, Glycemic Control, Body Weight Changes, Waist Circumference, Tolerance.

Is NCT05644717 still recruiting?

NCT05644717 is currently recruiting now. Last updated 21 March 2025.

Last reviewed 2025-03-21 · How we verify

NCT05644717: Ertu-NASH

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Erugliflozin On Liver Fat, Liver Fibrosis and Glycemic Control in Type II DM Patients With NASH/NAFLD

Recruiting now Phase 4 Last updated 21 March 2025

What this trial tests

Phase 4 trial testing Ertugliflozin 5 mg, 15mg in Liver Fat in 164 participants. Currently enrolling.

Timeline

1 March 2023

Primary endpoint
1 November 2025

1 December 2025

Quick facts

Lead sponsor	Getz Pharma
Phase	Phase 4
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	164
Start date	1 March 2023
Primary completion	1 November 2025
Estimated completion	1 December 2025
Sites	1 location across Pakistan

Drugs / interventions tested

Ertugliflozin 5 mg, 15mg — full drug profile →

Conditions studied

Liver Fat — all drugs for Liver Fat →
Liver Fibrosis — all drugs for Liver Fibrosis →
Glycemic Control — all drugs for Glycemic Control →
Body Weight Changes — all drugs for Body Weight Changes →

Sponsor

Getz Pharma — full company profile →

Who can join

Adults 18 to 65, any sex, with Liver Fat or Liver Fibrosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Open-label, prospective, single-arm, multicenter study to determine effects of Ertugliflozin on liver fat, liver fibrosis \& glycemic control in subjects with Type 2 Diabetes Mellitus (T2DM) with Non-Alcoholic Fatty Liver Disease (NAFLD)/Non-Alcoholic Steatohepatitis (NASH)

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Therapeutic management of metabolic dysfunction associated steatotic liver disease.
Zeng J, Fan JG, Francque SM. · · 2024 · cited 75× · PMID 38193865 · DOI 10.1002/ueg2.12525
Obesity, non-alcoholic fatty liver disease and hepatocellular carcinoma: current status and therapeutic targets.
Chen Y, Wang W, Morgan MP, Robson T, et al · · 2023 · cited 37× · PMID 37361533 · DOI 10.3389/fendo.2023.1148934
MetALD: Does it require a different therapeutic option?
Marek GW, Malhi H. · · 2024 · cited 21× · PMID 38820071 · DOI 10.1097/hep.0000000000000935
Pharmaceutical Strategies to Improve Druggability of Potential Drug Candidates in Nonalcoholic Fatty Liver Disease Therapy.
Amatya R, Lee D, Min KA, Shin MC. · · 2023 · cited 9× · PMID 37514148 · DOI 10.3390/pharmaceutics15071963

Verify or expand the search:

Other recruiting trials for Liver Fat

Currently open trials in the same condition.

NCT07122700 — Evaluation of Non-Invasive Tests for Metabolic Liver Disease · recruiting
NCT04899102 — Intermittent Fasting for NAFLD in Adults · NA · recruiting

Other Getz Pharma trials

Trials by the same sponsor.

NCT07174297 — Acotiamide vs Itopride in Postprandial Distress Syndrome · Phase 3 · not yet recruiting
NCT07031141 — Diabetes Foot Africa Region Registry · not yet recruiting
NCT06706609 — Classification of Adult-onset Diabetes in Five Subgroups in Pakistani Population · not yet recruiting
NCT05977647 — Medical Stone Expulsive Therapy for Acutely Obstructed Ureteric Calculi · Phase 4 · completed
NCT05556291 — Combination of Ertugliflozin And Sitagliptin Efficacy, Safety & Tolerability (CEASE Diabetes) Study · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05644717 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Getz Pharma
Last refreshed: 21 March 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05644717.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing